Imipenem/relebactam

Edina Avdic, Pharm.D.
Imipenem/relebactam is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Treatment of ccomplicated urinary tract infections, including pyelonephritis (cUTI) and ccomplicated intra-abdominal infections (cIAI) caused by susceptible gram-negative bacteria for patients who have limited or no alternative treatment options, who are ≥ 18 y/o.
    • Approval of these indications is based on limited clinical safety and efficacy data.

NON-FDA APPROVED USES

  • MDR infections including bacteremia, pneumonia, osteomyeltis

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Treatment of ccomplicated urinary tract infections, including pyelonephritis (cUTI) and ccomplicated intra-abdominal infections (cIAI) caused by susceptible gram-negative bacteria for patients who have limited or no alternative treatment options, who are ≥ 18 y/o.
    • Approval of these indications is based on limited clinical safety and efficacy data.

NON-FDA APPROVED USES

  • MDR infections including bacteremia, pneumonia, osteomyeltis

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: November 8, 2019